Beigene, LTD Form 4 insider transactions

Director Alessandro Riva acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Baker Bros. Advisors LP and affiliated entities report the grant of restricted share units to Felix J. Baker upon his election as a director of BeOne Medicines Ltd.

Principal Accounting Officer Titus B. Ball sold 136 American Depositary Shares to satisfy mandatory tax withholding obligations.

SVP and General Counsel Henry Lee Chan sold 871 American Depositary Shares to satisfy tax withholding obligations related to RSU vesting.

President and Global Head of R&D Lai Wang sold 1,367 American Depositary Shares to satisfy tax obligations.

President and COO Wu Xiaobin sold 1,484 American Depositary Shares to satisfy mandatory tax withholding obligations.

BeOne Medicines CEO John Oyler sold 4,940 American Depositary Shares to satisfy mandatory tax withholding obligations related to restricted share unit vesting.

Director Qingqing Yi of BeOne Medicines Ltd. reported a sale of American Depositary Shares (ADS) on June 1, 2026, related to a mandatory tax withholding provision.

Director Alessandro Riva sold 212 American Depositary Shares of BeOne Medicines Ltd. to satisfy mandatory tax withholding obligations.

Director Margaret Dugan sold 212 American Depositary Shares of BeOne Medicines Ltd. to satisfy tax withholding obligations.

Director Corsee Sanders disposed of 212 American Depositary Shares of BeOne Medicines Ltd. to satisfy tax withholding obligations.

Directors at BeOne Medicines Ltd. sold shares to cover mandatory tax withholding obligations following the vesting of restricted stock units.

SVP and General Counsel Henry Lee Chan exercised stock options and sold American Depositary Shares under a 10b5-1 plan.

BeOne Medicines Ltd. SVP, General Counsel Henry Lee reported a sale of American Depositary Shares executed under a pre-arranged 10b5-1 trading plan.

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, exercised stock options and sold American Depositary Shares under a pre-arranged trading plan.

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, exercised stock options and sold the resulting shares via American Depositary Shares under a pre-arranged trading plan.

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, exercised stock options and subsequently sold American Depositary Shares under a pre-arranged trading plan.

BeOne Medicines' President and Global Head of R&D, Wang Lai, acquired 427,895 restricted share units, increasing direct beneficial ownership.

BeOne Medicines Ltd. CEO John Oyler sold 100,000 American Depositary Shares over two days in December 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, executed pre-scheduled sales of American Depositary Shares and exercised stock options on December 10 and 11, 2025.

BeOne Medicines Director Corazon D. Sanders executed a sell-to-cover transaction, exercising options and selling American Depositary Shares.

BeOne Medicines' President and COO, Wu Xiaobin, reported the sale of 3,991 American Depositary Shares totaling approximately $1.5 million.

BeOne Medicines Ltd.'s President and COO, Wu Xiaobin, reported the sale of American Depositary Shares totaling 15,999 units over two days in November 2025.

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, executed a Rule 10b5-1 trading plan, exercising stock options and selling American Depositary Shares.

BeOne Medicines CEO John Oyler reported gifting over 1 million ordinary shares to a private foundation and other trusts.

BeOne Medicines Director and Scientific Advisory Board Chair, Xiaodong Wang, gifted 424,073 ordinary shares, reducing direct beneficial ownership.

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, exercised stock options and subsequently sold American Depositary Shares totaling approximately $3.7 million under a Rule 10b5-1 plan.

BeOne Medicines Ltd. CEO John Oyler sold 27,803 American Depositary Shares for approximately $9.06 million through a pre-arranged Rule 10b5-1 trading plan.

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, executed pre-planned sales of American Depositary Shares following option exercises on September 10, 2025.

BeOne Medicines Ltd. Director Xiaodong Wang reported a pre-planned gift of 148,096 ordinary shares effective September 9, 2025, under a Rule 10b5-1 plan.